ADAG: adagene.com Company Value to Net Income

Adagene Corp - graphic logo of issuer ADAG

This daily price chart for Adagene (ADAG) reflects a P/E ratio of -6.80. Adagene develops unique antibodies using proprietary AI algorithms, creating a significant barrier to entry for competitors in the sector. The business adheres to strict ESG principles and environmental safety standards. The brand's financial stability is underpinned by sufficient liquidity reserves and the successful completion of clinical trials for its developments.

adagene.com (ADAG) Price to Earnings Ratio: for the period 07/04/2022 - 11/11/2026

Analytical breakdowns for Adagene Inc (ADAG)

- price and consensus price forecast:
Stock Price Adagene Corp|ADAG - Consensus Target
- market capitalization information:
Market Value Adagene Inc.|ADAG - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Adagene|ADAG - Company Book Value|Market Cap to Net Assets Ratio adagene.com|ADAG - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Adagene|ADAG - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Adagene Corp|ADAG - Company Debts|Debt to Book Value Ratio Adagene Inc.|ADAG - Company Long-Term Debts|Short-Term Debt Adagene|Quick Ratio adagene.com
- earnings and market multiples details:
ADAG - Net Profit|Net Profit Forecast Adagene|ADAG - P/E Multiple|Forward P/E Multiple Adagene Corp|ADAG - PEG Multiple|Enterprise Value to EBITDA Multiple Adagene Inc.|ADAG - Operating profit EBITDA|Net earnings per one share for the last twelve months Adagene|ADAG - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months adagene.com|ADAG - Earnings growth in current year|Expected net earnings per share growth next year Adagene
Comprehensive company analysis:adagene.com ADAG
Signature product of Adagene Inc

The integration of robotic manipulators to accelerate molecule screening directly impacts the future profitability of Adagene (ADAG), which is reflected in the price-to-earnings ratio dynamics. This coefficient relates current market capitalization to net income, allowing investors to determine the degree of overpayment for the asset and assess business resilience amid potential reductions in government subsidies or changes in the tax regime.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN: P/E Multiple|Price to Earnings Multiple PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|P/E Multiple Upstream Bio, Inc.|P/E Multiple ZBIO|Immunome Bio (IMNM) - Market Cap to Net Income Ratio|P/E Multiple GOSS (Gossamer Bio, Inc.)|kalvista.com (KALV) - Market Cap to Earnings|SEPN - Price to Earnings Ratio|PVLA (Pieris Pharma) - Price to Earnings Multiple|SVRA: P/E Multiple|Market Cap to Earnings Rigel Corp (RIGL)|ANAB (AnaptysBio, Inc.) - P/E Multiple|P/E Multiple astriatx.com|P/E Multiple ENGN|RAPT Therapeutics Inc. - Price to Earnings Multiple|P/E Multiple JBIO (Aerovate Therapeutics)|P/E Multiple Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics - P/E Multiple|Market Cap to Net Income Ratio tizianalifesciences.com (TLSA)|Cabaletta Bio (CABA) - Price to Earnings Ratio|Market Cap to Net Income VTYX (Ventyx Biosciences Inc.)|THTX (Theratechnologies Inc) - P/E Multiple|AVTX: Company Value to Net Income|P/E Multiple ELDN|P/E Multiple agenusbio.com (AGEN)|Price to Earnings Ratio Climb Bio CLYM|Company Value to Net Income ZURA|ATYR - Price to Earnings Ratio|ImageneBio Inc (IMA) - Price to Earnings Ratio|STTK: P/E Multiple|Equillium (EQ) - P/E Multiple|Price to Earnings Ratio CNTB|IMUX: Company Value to Net Income|P/E Multiple ATRA|Business Payback Period inflarx.de|Price to Earnings Ratio X4 Pharmaceuticals XFOR|ACET - Price to Earnings Ratio|CELU - Price to Earnings Ratio|INmune Bio Inc (INMB) - Price to Earnings Ratio|BRNS (Barinthus Bio) - Price to Earnings Ratio|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SAB Biotherapeutics|Price to Earnings Multiple AKTX (akaritx.com)|P/E Multiple ENLV|QTTB - Market Cap to Earnings|P/E Multiple GOVX (GeoVax Labs Inc)|P/E Multiple Edesa Biotech Corp EDSA|iBio, Inc. - P/E Multiple|CARM (Carisma Therapeutics) - Price to Earnings Multiple|XTLB: P/E Multiple|Bolt Biotherapeutics, Inc. (BOLT) - P/E Multiple|HCWB (HCW Biologics, Inc.) - P/E Multiple|APVO - Market Cap to Net Income Ratio|P/E Multiple AIM|ADTX - Market Cap to Earnings|Price to Earnings Ratio GRI Bio GRI|XRTX: Price to Earnings Multiple|ReShape Lifesciences - P/E Multiple|Market Cap to Earnings Revelation Biosciences Corp|INDP: P/E Multiple|scinai.com (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|Price to Earnings Multiple AFMD (Affimed Therapeutics)|P/E Multiple ALLK|P/E Multiple hookipapharma.com (HOOK)|P/E Multiple IGMS (IGM Biosciences)|Market Cap to Net Income Ratio iteostherapeutics.com|OCEA - Price to Earnings Ratio|Market Cap to Net Income TCBP|THRD: P/E Multiple